Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2025 02:45 ET | Source: Enterome

Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025

Survival in 20 patients with MSS/pMMR mCRC at a median follow-up of 15.4 months was 40% at 12 months; median survival is currently 11.3 monthsSurvival has currently reached plateau, with 34% (7/20) of...
May 30, 2025 01:00 ET | Source: Regeneron Pharmaceuticals, Inc.

Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically...
May 29, 2025 17:51 ET | Source: MUSE Microscopy, Inc.

Leading with Light: MUSE Microscopy Illuminates the Next Era of Oncology at ASCO

IRVINE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- MUSE Microscopy, (the “Company”, “we”, “our”) a leader in slide-free, tissue-to-digital™ pathology solutions, is excited to announce its...
May 29, 2025 17:00 ET | Source: Cytek Biosciences, Inc.

Cytek® Biosciences Is Setting the New Standard for Full Spectrum Flow Cytometry with the New Cytek Aurora™ Evo Flow Cytometer

Cytek has announced the launch of the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on its flagship Cytek Aurora system.
May 29, 2025 16:15 ET | Source: Alumis Inc.

Alumis to Present at the Jefferies Global Healthcare Investor Conference

Alumis to present at Jefferies Global Healthcare Conference on June 4, 2025
May 29, 2025 16:05 ET | Source: Avadel Pharmaceuticals plc

Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025

– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who...
May 29, 2025 16:05 ET | Source: Annexon Biosciences

Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with...
May 29, 2025 16:05 ET | Source: NextCure

NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025

LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling...
May 29, 2025 16:01 ET | Source: Kiniksa Pharmaceuticals, Ltd.

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will present at the following investor conferences in June: ...
May 29, 2025 16:01 ET | Source: Beam Therapeutics

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that...